Reported results
- Cash and cash equivalents were $66.8 million as of September 30, 2026.
- Research & Development (R&D) expenses were $14.9 million for the third quarter of 2026.
- Non-cash stock-based compensation included in R&D expense was $0.8 million for the third quarter of 2026.
- General & Administrative (G&A) expenses were $5.6 million for the third quarter of 2026.
- Non-cash stock-based compensation included in G&A expense was $0.9 million for the third quarter of 2026.
- Net loss was $18.9 million, or $0.08 loss per share, for the third quarter ended September 30, 2026.
Guidance
- Tenaya expects that cash and cash equivalents will be sufficient to fund planned operations into the fourth quarter of 2027.
- Tenaya intends to initiate at least one company-sponsored Phase 2 clinical trial for TN-301 in the second half of 2027.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-04 (8-K, Item 2.02). Read the original filing on sec.gov.
